Related references
Note: Only part of the references are listed.Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Tumor Heterogeneity and Personalized Medicine
Dan L. Longo
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
Sen Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics
Laurent Becquement et al.
PHARMACOGENOMICS (2011)
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
Eric J. Peters et al.
PHARMACOGENOMICS (2011)
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
Ursula Amstutz et al.
PHARMACOGENOMICS (2011)
Economic Opportunities and Challenges for Pharmacogenomics
Patricia A. Deverka et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
Andre B. P. van Kuilenburg et al.
HUMAN GENETICS (2010)
Cost Effectiveness of Pharmacogenomics A Critical and Systematic Review
William B. Wong et al.
PHARMACOECONOMICS (2010)
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020
R. Stephanie Huang et al.
PHARMACOGENOMICS (2010)
Genetics of caffeine consumption and responses to caffeine
Amy Yang et al.
PSYCHOPHARMACOLOGY (2010)
Pharmacogenomics: a systems approach
Liewei Wang
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2010)
Pharmacogenetics and Pharmacogenomics of Anticancer Agents
R. Stephanie Huang et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
Ursula Amstutz et al.
PHARMACOGENOMICS (2009)
Pharmacogenomics: candidate gene identification, functional validation and mechanisms
Liewei Wang et al.
HUMAN MOLECULAR GENETICS (2008)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Heritability in the genomics era - concepts and misconceptions
Peter M. Visscher et al.
NATURE REVIEWS GENETICS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
被撤回的出版物: Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer (Retracted article. See vol. 28, pg. 5229, 2010)
David S. Hsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity
Nicolas Magne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1
Nauder Faraday et al.
CIRCULATION (2007)
Advanced sequencing technologies and their wider impact in microbiology
Neil Hall
JOURNAL OF EXPERIMENTAL BIOLOGY (2007)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe
M. Elske van den Akker-van Marle et al.
PHARMACOGENOMICS (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia
M Stanulla et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Pharmacogenomics in cancer therapy: is host genome variability important?
WP Petros et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Genome-wide discovery of loci influencing chemotherapy cytotoxicity
JW Watters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity
ME Dolan et al.
CANCER RESEARCH (2004)
Pharmacogenetics and pharmacogenomics in drug discovery and development: An overview
K Lindpaintner
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2003)
The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics
HL McLeod et al.
PHARMACOGENOMICS (2002)
Accessing genetic variation:: Genotyping single nucleotide polymorphisms
AC Syvänen
NATURE REVIEWS GENETICS (2001)
Pharmacogenetics and the practice of medicine
AD Roses
NATURE (2000)
Share Paper
